(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 59.04% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Rhythm Pharmaceuticals's revenue in 2026 is $217,165,000.On average, 18 Wall Street analysts forecast RYTM's revenue for 2026 to be $20,165,034,284, with the lowest RYTM revenue forecast at $17,783,526,190, and the highest RYTM revenue forecast at $21,593,253,814. On average, 17 Wall Street analysts forecast RYTM's revenue for 2027 to be $37,570,945,810, with the lowest RYTM revenue forecast at $29,215,450,364, and the highest RYTM revenue forecast at $44,766,184,218.
In 2028, RYTM is forecast to generate $61,168,093,052 in revenue, with the lowest revenue forecast at $43,655,270,659 and the highest revenue forecast at $82,924,454,470.